Back to search results

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE2

Conditions

Refractory Multiple Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Vancouver Cancer Center, Vancouver, British Columbia, Canada

    Contact: Study coordinator (Christopher Venner, MD) · 604-877-6000

  • Juravinski Cancer Center, Hamilton, Ontario, Canada

    Contact: Study coordinator (Hira Mian, MD) · hira.mian@medportal.ca · 905-387-9495

  • Kingston General Hospital, Kingston, Ontario, Canada

    Contact: Study coordinator (Ashlee Young, Trial Activation Coordinator) · ashlee.young@kingstonhsc.ca · 613-549-6666
    Contact: Principal Investigator (Bethany Monteith, MD)

  • London Health Science Centre - Victoria Hospital, London, Ontario, Canada

  • London Health Science Centre - Victoria Hospital, London, Ontario, Canada

    Contact: Study coordinator (Martha de Lacerda Louzada, MD) · Martha.Louzada@lhsc.on.ca

  • Ottawa Hospital, Ottawa, Ontario, Canada

    Contact: Study coordinator (Arleigh Robertson McCurdy, MD) · 613-737-8899
Study leads

  • Hira Mian, MD

    Principal Investigator

    McMaster University

  • Jim Wright, MD

    Study Director

    OCOG - McMaster University

View source on ClinicalTrials.gov(opens in a new tab)